InspireMD

Stent System Technology for Preventing Embolization

Health Tech & Life Sciences
Public on NYSE on Apr 2011
Follow

Company Overview

Snapshot

Founded in April 2005, InspireMD operates with 51–200 employees and has raised a total of $229.48 million across 11 funding rounds from 5 investors. In August 2025, the company secured funding from lead investors OrbiMed and Marshall Wace.

Business overview

InspireMD is a commercial-stage medical device company specializing in proprietary stent designs with integrated embolic prevention systems (EPS) for neurovascular protection and stroke prevention. The company utilizes its MicroNet technology to address shortcomings in conventional carotid stenting and surgery, aiming to establish its products as the industry standard for sustained embolic protection. InspireMD is focused on expanding its portfolio of solutions and applying its MicroNet technology to other indications, such as peripheral artery procedures, serving the healthcare industry with a focus on vascular, cardiology, and neurovascular treatments.

Strategic signal

In October 2024, InspireMD announced the approval of its Investigational Device Exemption (IDE) application for the CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System. This development signals significant progress in the company's clinical pipeline and its commitment to advancing its core technology, potentially paving the way for broader market access and adoption of its carotid stenting solutions.

Log in to access full profile ›

Company Intelligence Q&A

What significant regulatory milestone did InspireMD achieve in September 2024?
In September 2024, InspireMD announced the submission of a Premarket Approval Application to the FDA for its CGuard™ Prime Carotid Stent System, seeking U.S. regulatory approval.
What was a key strategic move by InspireMD in October 2024?
In October 2024, InspireMD announced the establishment of its global headquarters in Miami, Florida, to support the anticipated U.S. launch and commercialization of the CGuard Prime Carotid Stent System.
What was the outcome of InspireMD's Q3 2023 financial results?
InspireMD reported its Third Quarter 2023 financial results in November 2023, with CGuard EPS Revenue increasing by 9%.
Which investors participated in InspireMD's August 2025 financing round?
In August 2025, InspireMD secured financing from OrbiMed and Marshall Wace. The company announced $58 million in combined financings and a new addition to its board of directors, as reported by Vascular News.
What strategic partnership did InspireMD announce in September 2022?
In September 2022, InspireMD announced a strategic outsourcing partnership with NAMSA to accelerate new product development.
Log in to access full profile ›

External links